| Theresa Ellen Jones, MD | |
|
12255 De Paul Dr Ste 360, Bridgeton, MO 63044-2513 | |
| (314) 739-9293 | |
| (314) 739-3968 |
| Full Name | Theresa Ellen Jones |
|---|---|
| Gender | Female |
| Speciality | Ophthalmology |
| Experience | 25 Years |
| Location | 12255 De Paul Dr Ste 360, Bridgeton, Missouri |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053428771 | NPI | - | NPPES |
| 207538109 | Medicaid | MO |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 2004001643 (Missouri) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ssm Depaul Health Center | Bridgeton, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Comprehensive Eye Care And Surgery Inc | 3577504471 | 2 |
News Archive
OSI Pharmaceuticals, Inc. announced today that the U.S. Patent & Trademark Office has issued a "Notice of Allowance" in OSI's reissue application for U.S. Patent No.5,747,498 (the ‘498) composition of matter patent for Tarceva® (erlotinib). The reissued patent will replace the original ‘498 patent and have the same November 2018 expiration date.
Getinge Canada Limited is honoured to be named among the Top 50 Best Small and Medium Employers in Canada for 2009. This reflects positively on the employees and their engagement in the growth of this organization. The study, now in its sixth year, is published in the Globe and Mail and PROFIT Magazine.
Scientists hope to have paved the way for the development of potentially new life-saving treatments to be administered to seriously injured patients in the critical first hour of injury.
A new guideline from the American Academy of Neurology, developed in full collaboration with the Child Neurology Society, finds that children with microcephaly that is, children whose head size is smaller than that of 97 percent of childrenare at risk of neurologic and cognitive problems and should be screened for these problems. The guideline is published in the September 15, 2009, issue of Neurology®, the medical journal of the American Academy of Neurology.
› Verified 2 days ago
| Entity Name | Comprehensive Eye Care And Surgery Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417065129 PECOS PAC ID: 3577504471 Enrollment ID: O20050520000739 |
News Archive
OSI Pharmaceuticals, Inc. announced today that the U.S. Patent & Trademark Office has issued a "Notice of Allowance" in OSI's reissue application for U.S. Patent No.5,747,498 (the ‘498) composition of matter patent for Tarceva® (erlotinib). The reissued patent will replace the original ‘498 patent and have the same November 2018 expiration date.
Getinge Canada Limited is honoured to be named among the Top 50 Best Small and Medium Employers in Canada for 2009. This reflects positively on the employees and their engagement in the growth of this organization. The study, now in its sixth year, is published in the Globe and Mail and PROFIT Magazine.
Scientists hope to have paved the way for the development of potentially new life-saving treatments to be administered to seriously injured patients in the critical first hour of injury.
A new guideline from the American Academy of Neurology, developed in full collaboration with the Child Neurology Society, finds that children with microcephaly that is, children whose head size is smaller than that of 97 percent of childrenare at risk of neurologic and cognitive problems and should be screened for these problems. The guideline is published in the September 15, 2009, issue of Neurology®, the medical journal of the American Academy of Neurology.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Theresa Ellen Jones, MD 12255 De Paul Dr Ste 360, Bridgeton, MO 63044-2513 Ph: (314) 739-9293 | Theresa Ellen Jones, MD 12255 De Paul Dr Ste 360, Bridgeton, MO 63044-2513 Ph: (314) 739-9293 |
News Archive
OSI Pharmaceuticals, Inc. announced today that the U.S. Patent & Trademark Office has issued a "Notice of Allowance" in OSI's reissue application for U.S. Patent No.5,747,498 (the ‘498) composition of matter patent for Tarceva® (erlotinib). The reissued patent will replace the original ‘498 patent and have the same November 2018 expiration date.
Getinge Canada Limited is honoured to be named among the Top 50 Best Small and Medium Employers in Canada for 2009. This reflects positively on the employees and their engagement in the growth of this organization. The study, now in its sixth year, is published in the Globe and Mail and PROFIT Magazine.
Scientists hope to have paved the way for the development of potentially new life-saving treatments to be administered to seriously injured patients in the critical first hour of injury.
A new guideline from the American Academy of Neurology, developed in full collaboration with the Child Neurology Society, finds that children with microcephaly that is, children whose head size is smaller than that of 97 percent of childrenare at risk of neurologic and cognitive problems and should be screened for these problems. The guideline is published in the September 15, 2009, issue of Neurology®, the medical journal of the American Academy of Neurology.
› Verified 2 days ago
Dundoo Raghunandan, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 12255 De Paul Dr, Suite 420, Bridgeton, MO 63044 Phone: 314-291-5000 Fax: 314-291-4932 |